Tango Therapeutics, Inc.
TNGXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M | $7.7M |
| Operating income | −$111.3M | −$145.6M | −$114.2M | −$111.1M | −$58.2M | −$181,428 |
| Net income | −$101.6M | −$130.3M | −$101.7M | −$108.2M | −$58.2M | −$123,046 |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M | $168.3M |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M | $6.0M |
| Equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M | $5.0M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | — |
| Shares out. | 108.1M | 106.7M | 88.2M | 87.7M | 21.4M | 5.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −178.4%
- Net margin
- −162.9%
- Return on equity
- −29.3%
- Return on assets
- −25.5%
- Return on capital (ROCE)
- −29.5%
- Liabilities / assets
- 13.2%
- Debt / equity
- 0.15×
- Book value / share
- $3.20
- Revenue growth (YoY)
- 48.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 5.58safe
- Accruals / assets
- 9.4%moderate
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2026-01Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- Phase 1/2Recruitingreadout ~2026-05Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Phase 1/2Recruitingreadout ~2027-03-31Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Phase 1/2Recruitingreadout ~2027-06Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Nextech Crossover I Gp S.A R.L.Passive (13G)May 15, 2026
- Rtw Investments, LpPassive (13G)May 15, 2026
- Tcg Crossover Gp Ii, LlcPassive (13G)May 15, 2026
- Woodline Partners LpPassive (13G)May 15, 2026
- Adage Capital Management, L.P.Passive (13G)May 13, 2026
- Farallon Capital Partners, L.P.Passive (13G)May 11, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Invus Global Management, LlcPassive (13G)May 4, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Ecor1 Capital, LlcPassive (13G)Feb 17, 2026
- Third Rock Ventures Iv, L.P.Activist (13D)Feb 10, 2026
- Farallon Partners L L C/CaPassive (13G)Feb 6, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Crystal AdamOfficer — President, R&D | May 1, 2026 | Option exercise | 27,000 | $5.20 |
| Gall MatthewOfficer — Chief Financial Officer | May 1, 2026 | Grant | 40,000 | $0.00 |
| Lee SungDirector | Apr 29, 2026 | Grant | 12,300 | $0.00 |
| Crystal AdamOfficer — President, R&D | Apr 15, 2026 | Option exercise | 38,460 | $5.20 |
| Crystal AdamOfficer — President, R&D | Apr 1, 2026 | Option exercise | 27,000 | $5.20 |
| Crystal AdamOfficer — President, R&D | Mar 25, 2026 | Option exercise | 12,000 | $5.20 |
| Crystal AdamOfficer — President, R&D | Mar 5, 2026 | Sell | 20,251 | $15.00 |
| Crystal AdamOfficer — President, R&D | Feb 25, 2026 | Sell | 54,345 | $12.77 |
| Beckman DaniellaOfficer — Chief Financial Officer | Feb 2, 2026 | Grant | 44,330 | $0.00 |
| Weber BarbaraOfficer — Director, Executive Chair | Feb 2, 2026 | Grant | 37,522 | $0.00 |
| Crystal AdamOfficer — President, R&D | Feb 2, 2026 | Grant | 47,460 | $0.00 |
| Peters MalteOfficer — President & CEO | Jan 8, 2026 | Grant | 350,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 31.8M | 10.0 | -16.8% |
| Apr 30, 2026 | 38.3M | 12.5 | -5.0% |
| Apr 15, 2026 | 40.2M | 14.4 | -0.3% |
| Mar 31, 2026 | 40.4M | 12.1 | -14.6% |
| Mar 13, 2026 | 47.2M | 9.8 | -3.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Director / officer changeMay 13, 2026
- Director / officer changeMay 8, 2026
- Director / officer change · Regulation FD disclosureApr 15, 2026
- Results of operationsMar 5, 2026
- Results of operations · Director / officer change · Regulation FD disclosureJan 8, 2026
- Director / officer changeJan 5, 2026
- Entered a material agreement · Terminated a material agreementNov 21, 2025
- Results of operationsNov 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- 8-KMay 13, 2026
- 10-QMay 13, 2026
- SCHEDULE 13G/AMay 13, 2026
- SCHEDULE 13G/AMay 11, 2026
- 8-KMay 8, 2026
- SCHEDULE 13GMay 6, 2026
- 4May 5, 2026
- 4May 5, 2026
- SCHEDULE 13G/AMay 4, 2026
- 4May 1, 2026
- 144May 1, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.